Picard Medical Inc

Picard Medical Inc(PMI)股票分析

$8.789

+1.051 (+11.96%)收盤時

Loading chart…
最高
9.140
開盤
7.850
成交量加權均價
8.54
成交量
44.87K
市值
—
最低
7.683
成交金額
383.06K
企業價值/稅息折舊攤銷前利潤(TTM)
-2.20

Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.

AI 分析 of Picard Medical Inc (PMI)

買進

Picard Medical Inc (PMI) appears to be a good buy right now due to its recent revenue growth of 39% in Q2 2026, reaching approximately $3.0 million, and a notable improvement in gross margin to 20.9%. However, the main risk is the ongoing net loss of approximately $5.7 million for the same quarter, which indicates that while the company is improving, it still faces significant financial challenges.

估值指標

Picard Medical Inc(PMI)目前預期本益比為 0.00,5 年平均預期本益比為 0.00。

預期本益比

嚴重低估
5 年均值 P/E
0.00
目前P/E
0.00
高估
0.00
低估
0.00

預期 EV/EBITDA

低估
5 年均值 EV/EBITDA
-0.74
目前EV/EBITDA
-2.20
高估
0.15
低估
-1.62

預期股價營收比

高估
5 年均值 P/S
1.45
目前P/S
3.11
高估
2.95
低估
-0.04

事件時間軸

2026-10-16 (ET)

11:30:00

Picard Medical Inc Trading Halted

2026-10-15 (ET)

15:30:00

Picard Medical Inc Trading Halted

2026-10-05 (ET)

10:30:00

Picard Medical Inc Trading Halted

2026-08-25 (ET)

10:00:00

Picard Medical Inc Trading Halted

2026-07-21 (ET)

21:00:00

Picard Medical Approves 1-for-50 Reverse Stock Split

資訊

PMI 常見問題 —— 由 Alphio AI 解答

Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber. It operates in the Healthcare sector.

Picard Medical Inc (PMI) appears to be a good buy right now due to its recent revenue growth of 39% in Q2 2026, reaching approximately $3.0 million, and a notable improvement in gross margin to 20.9%. However, the main risk is the ongoing net loss of approximately $5.7 million for the same quarter, which indicates that while the company is improving, it still faces significant financial challenges.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易